Wall Street consensus, price target range, and equity research thesis
Wall Street currently rates ABT buy with a 12-month price target of $122 (+17.1% upside). The sections below cover the bull case, key risks, and latest earnings context for Abbott Laboratories.
Analyst ratings update weekly. Get ABT's next verdict in your inbox.
Free. No account needed. Unsubscribe any time.
Analyst Research Summary
A structured look at the bull case, the risks, and the most recent earnings execution for ABT.
ABT beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
What keeps the long thesis intact
Wall Street rates ABT buy, giving the bull case institutional backing from 41 analysts.
What can break the setup quickly
Watch whether new negative commentary on ABT points to these structural risks or is simply reacting to short-term price moves.
Last Quarter
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Stock snapshot, live price chart, key ratios, and company profile.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ABT stock.
ABT has modest upside — analysts rate it "Buy" with a $122 target, implying +17.1% from today's $103.73. This is informational only — verify the data and consider your own risk tolerance before deciding.
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +17.1% upside to the $122 target.
ABT's consensus 12-month price target is $122, set by 41 Wall Street analysts. The bull case high is $143 and the bear case low is $92. From the current price of $103.73, this implies +17.1% upside.
ABT appears undervalued — the $122 consensus target is +17.1% above today's $103.73. It trades at a forward P/E of 18.8x. Targets range from $92 (bear) to $143 (bull), reflecting different assumptions about growth and margins.
ABT reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $122 target. Consider position sizing rather than going all-in pre-print.
Of 41 analysts covering Abbott Laboratories (ABT): 0 Strong Buy, 32 Buy, 9 Hold, 0 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $122 (range $92–$143). Bullish analysts outnumber bearish by more than 2-to-1.
No analyst currently rates ABT a Sell, but the 9 Hold ratings reflect concerns about valuation, execution risk, or near-term catalysts. See the Bull vs. Risk cards above for the specific theses on Abbott Laboratories.
Financial Data & Software Notice: VCP Scanner is an educational financial research database and stock screening software platform. VCP Scanner does not generate, recommend, or package trade decisions, buy/sell signals, or personalized investment advice. Consensus ratings and price targets reflect aggregated third-party Wall Street analyst research from public SEC filings. See our Terms of Service and Privacy Policy.